An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia

Trial Profile

An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Thrombocytopenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
    • 02 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
    • 12 Dec 2017 According to the results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology, the study had an observation arm which was discontinued out of consideration for trial beneficence, and the trial continued accrual as a single arm study of romiplostim
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top